| Authors: |
Yang H; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arita K; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bowman K; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; University of Texas MD Ander Cancer Center UT Health Houston Graduate School of Biological Sciences, Houston, TX, USA., Chihara D; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Henderson J; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rost G; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rojas E; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Parsons S; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lakra P; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abedin A; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Neelapu SS; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strati P; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nastoupil LJ; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad L; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Iyer SP; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez A; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hagemeister FB; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Malpica L; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HJ; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hilton L; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Davis RE; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin JR; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Inghirami G; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA., Vega F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
